BackInsulet Overview
Insulet Corporation

Insulet Target Price

Analysts' average 12-month price target for Insulet is $210.

Get informed when a big investor buys or sells

+ Follow

Share Price

$148.03

Average Target Price

$205.6238.9% upside

29 analysts in the last 4 months

High: $280 | Low: $144

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-06Robert W. BairdJeff Johnson$17518.2% upsideOpen
2026-08-06Bernstein$17518.2% upsideOpen
2026-08-06Leerink PartnersMike Kratky$1452% downsideOpen
2026-08-06RBC Capital$1608.1% upsideOpen
2026-08-06Raymond JamesJayson Bedford$18021.6% upsideOpen
2026-08-06Canaccord GenuityWilliam Plovanic$17920.9% upsideOpen
2026-08-05Wells FargoLarry Biegelsen$1442.7% downsideOpen
2026-08-05Truist Financial$1533.4% upsideOpen
2026-07-28UBS$17417.5% upsideOpen
2026-07-13Truist Financial$21041.9% upsideOpen
2026-07-13RBC Capital$24565.5% upsideOpen
2026-07-10Stifel Nicolaus$22552% upsideOpen
2026-07-06Evercore ISI$18021.6% upsideOpen
2026-06-23Deutsche Bank$19028.4% upsideOpen
2026-06-11UBS$21947.9% upsideOpen
2026-06-11Truist FinancialRichard Newitter$21947.9% upsideOpen
2026-06-08Raymond James$21645.9% upsideOpen
2026-05-27Goldman SachsDavid Roman$20538.5% upsideOpen
2026-05-26BTIG$23558.8% upsideOpen
2026-05-07Goldman Sachs$23760.1% upsideOpen
2026-05-07RBC CapitalShagun Singh$28089.2% upsideOpen
2026-05-07Truist FinancialRichard Newitter$25068.9% upsideOpen
2026-05-07Evercore ISI$20035.1% upsideOpen
2026-05-07Oppenheimer$21041.9% upsideOpen
2026-05-07Stifel Nicolaus$25068.9% upsideOpen
2026-05-07Canaccord GenuityWilliam Plovanic$24968.2% upsideOpen
2026-05-07Bernstein$20035.1% upsideOpen
2026-05-07BarclaysMatt Miksic$19833.8% upsideOpen
2026-05-06BTIG$26075.6% upsideOpen
2026-04-24Redburn Partners$22048.6% upsideOpen
2026-04-15Truist FinancialRichard Newitter$315112.8% upsideOpen
2026-04-14RBC CapitalShagun Singh$325119.6% upsideOpen
2026-02-19Truist Financial$360143.2% upsideOpen
2026-02-19Evercore ISI$340129.7% upsideOpen
2026-02-19Goldman SachsDavid Roman$326120.2% upsideOpen
2026-02-19Oppenheimer$300102.7% upsideOpen
2026-02-19Bernstein$330122.9% upsideOpen
2026-02-19Barclays$28693.2% upsideOpen
2026-02-18Canaccord GenuityWilliam Plovanic$435193.9% upsideOpen
2026-02-04Stifel Nicolaus$350136.4% upsideOpen
2026-01-12Barclays$27485.1% upsideOpen
2026-01-09BernsteinLee Hambright$380156.7% upsideOpen
2026-01-09Goldman SachsDavid Roman$365146.6% upsideOpen
2025-12-18Truist Financial$390163.5% upsideOpen
2025-12-17Canaccord Genuity$450204% upsideOpen
2025-12-16Evercore ISI$370149.9% upsideOpen
2025-11-24Canaccord Genuity$432191.8% upsideOpen
2025-11-21Truist FinancialRichard Newitter$412178.3% upsideOpen
2025-11-21RBC CapitalShagun Singh$380156.7% upsideOpen
2025-11-21BTIG$380156.7% upsideOpen

Insulet (PODD) FAQ

Insulet posts a target price of $210. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $210 for PODD means covering analysts, on average, see the stock 38.9% upside of $148.03 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for PODD's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Insulet's other metric pages and overview cover the third.

Judging Insulet against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $210 here, then scan peer and history charts to see if the gap is persistent.